Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Sep 30;243:174-81.
doi: 10.1016/j.psychres.2016.06.024. Epub 2016 Jun 17.

Psychiatric Comorbidities in Opioid-Dependent Patients Undergoing a Replacement Therapy Programme in Spain: The PROTEUS Study

Affiliations

Psychiatric Comorbidities in Opioid-Dependent Patients Undergoing a Replacement Therapy Programme in Spain: The PROTEUS Study

Carlos Roncero et al. Psychiatry Res. .

Abstract

Opioid-dependent patients show a high rate of psychiatric comorbidities. The prevalence and characteristics of patients with dual diagnosis have not been well established in Spanish opioid agonist treatment (OAT) programmes. Thus, 621 opioid-dependent patients enrolled in OAT programmes were assessed, using the EuropASI questionnaire, for psychiatric comorbidities, which were detected in 67% of patients (anxiety 53%, mood disorders 48%, sleep disorders 41%, substance-related disorders 36%). In addition, compared with patients without a dual diagnosis, patients with dual pathology were significantly older, used benzodiazepines and cannabis in significantly greater percentages, and showed significantly more frequent infectious and non-infectious comorbidities, worse overall working status, a lower proportion of drivers and higher levels of severity regarding medical, employment, alcohol, legal, family and psychological issues. Therefore, the data showed a very high prevalence of psychiatric comorbidity in opioid-dependent patients receiving OAT in Spain and several problems frequently associated with patients with dual diagnosis. Physicians treating opioid-dependent patients should be aware of these facts to correctly identify and manage patients with a dual diagnosis.

Keywords: Comorbidity; Dual diagnosis; EuropASI questionnaire; Methadone; Opioid agonist treatment; Opioid dependence; Psychiatric.

Similar articles

See all similar articles

Cited by 8 articles

See all "Cited by" articles
Feedback